Positive peritoneal cytology in gastric cancer is classified as M1 disease by the 7(th) Edition of American Joint Committee on Cancer staging system. With the introduction of laparoscopy and peritoneal washing cytology in the staging of gastric cancer a new category of patients has been identified. These are patients with no macroscopic peritoneal metastases but with peritoneal cytology positive (P0C1). Prognosis and treatment of such patients represent a controversial issue. We evaluate the state of the art of staging system in gastric cancer and discuss standardisation in staging and treatment procedures. There is still a lack of uniformity in the use of laparoscopy with peritoneal cytology in clinical decision making and in the surgical treatment for gastric cancer. Survival of this patient subset remains poor. Multimodal therapies and new therapeutic strategies are required to improve the survival of these patients.
Prognosis and treatment of patients with positive peritoneal cytology in advanced gastric cancer / F. Frattini, S. Rausei, C. Chiappa, F. Rovera, L. Boni, G. Dionigi. - In: WORLD JOURNAL OF GASTROINTESTINAL SURGERY. - ISSN 1948-9366. - 5:5(2013), pp. 135-137. [10.4240/wjgs.v5.i5.135]
Prognosis and treatment of patients with positive peritoneal cytology in advanced gastric cancer
L. Boni;G. Dionigi
2013
Abstract
Positive peritoneal cytology in gastric cancer is classified as M1 disease by the 7(th) Edition of American Joint Committee on Cancer staging system. With the introduction of laparoscopy and peritoneal washing cytology in the staging of gastric cancer a new category of patients has been identified. These are patients with no macroscopic peritoneal metastases but with peritoneal cytology positive (P0C1). Prognosis and treatment of such patients represent a controversial issue. We evaluate the state of the art of staging system in gastric cancer and discuss standardisation in staging and treatment procedures. There is still a lack of uniformity in the use of laparoscopy with peritoneal cytology in clinical decision making and in the surgical treatment for gastric cancer. Survival of this patient subset remains poor. Multimodal therapies and new therapeutic strategies are required to improve the survival of these patients.File | Dimensione | Formato | |
---|---|---|---|
WJGS-5-135.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
509.29 kB
Formato
Adobe PDF
|
509.29 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.